RLMD: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.